Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (164)	12/22/2005 6:58:14 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 332

Actually, for $50M AZN bought “option” for all 1067 right. Does anyone know are this $50M repayable IF ARISE trial failed? On the other hand, deal is very lucrative for AGIX IF ARISE is success. Royalty are probably in 20-30% range (maybe going to 35%) for the drug that have relatively large market potential (depend on results for other indications). Bottom line, IMO this will continue to be true binary event for 2H-2006, unless AZN had opportunity to luck on "blinded” results at selected sites!!!! Miljenko PS: AZN also have another interesting (multi $BBB) late stage PIII candidate for stroke, with RNVS.